Annals of the rheumatic diseases

publication venue for

Development of CARRA/PReS-endorsed consensus Core and Expanded Datasets in childhood-onset systemic lupus erythematosus for international registry-based research. 2024
Lupus and inflammatory bowel disease share a common set of microbiome features distinct from other autoimmune disorders. 2024
Racial variability in immune responses only partially explains differential systemic sclerosis disease severity. 2024
Response to: Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria' by Miro-Mur et al.. 83. 2024
Response to: Correspondence on '2023 ACR/EULAR antiphospholipid syndrome classification criteria' by Tang et al.. 83. 2024
Response to: Correspondence on 'ACR/EULAR antiphospholipid syndrome classification criteria' by Damoiseaux and van Beers.. 83. 2024
Lower body mass and lower adiposity are associated with differential responses to two treatment strategies for rheumatoid arthritis. 2024
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023. 2023
Validation of a new glucocorticoid-specific Patient-Reported Outcome Questionnaire (the Steroid PRO). 2023
2023 ACR/EULAR antiphospholipid syndrome classification criteria.. 82. 2023
Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis.. 82. 2023
Rituximab versus azathioprine for maintenance of remission for patients with ANCA-associated vasculitis and relapsing disease: an international randomised controlled trial.. 82. 2023
2022 EULAR points to consider for the measurement, reporting and application of IFN-I pathway activation assays in clinical research and practice.. 82. 2023
Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission. 2022
TGFβ promotes low IL10-producing ILC2 with profibrotic ability involved in skin fibrosis in systemic sclerosis.. 80. 2021
Charles L Christian: model physician scientist and mentor.. 80. 2021
European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance.. 80. 2021
Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement.. 80. 2020
Circulating microbial small RNAs are altered in patients with rheumatoid arthritis.. 79. 2020
Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities.. 79. 2020
Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis.. 79. 2020
Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile.. 79. 2019
Emergent high fatality lung disease in systemic juvenile arthritis.. 78. 2019
Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout.. 78. 2019
Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures.. 78. 2019
TNF-induced inflammatory genes escape repression in fibroblast-like synoviocytes: transcriptomic and epigenomic analysis.. 78. 2019
Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39.. 78. 2019
Non-classical monocytes as mediators of tissue destruction in arthritis.. 77. 2018
Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies.. 77. 2018
Cigarette smoking and the risk of systemic lupus erythematosus, overall and by anti-double stranded DNA antibody subtype, in the Nurses' Health Study cohorts.. 77. 2017
Targeting the RhoA-ROCK pathway to reverse T-cell dysfunction in SLE.. 76. 2016
Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity.. 76. 2016
Combined role of vitamin D status and CYP24A1 in the transition to systemic lupus erythematosus.. 76. 2016
Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study.. 76. 2016
Sustained improvements in MRI outcomes with abatacept following the withdrawal of all treatments in patients with early, progressive rheumatoid arthritis.. 75. 2016
Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification.. 75. 2016
Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis.. 75. 2016
Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production.. 75. 2016
Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.. 75. 2015
Increased pretreatment serum IFN-β/α ratio predicts non-response to tumour necrosis factor α inhibition in rheumatoid arthritis.. 75. 2015
The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis.. 75. 2015
Association of hyperlipidaemia, inflammation and serological status and coronary heart disease among patients with rheumatoid arthritis: data from the National Veterans Health Administration.. 75. 2015
Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period.. 74. 2014
Neutrophil extracellular traps regulate IL-1β-mediated inflammation in familial Mediterranean fever.. 75. 2014
Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA.. 75. 2014
Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.. 74. 2014
The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis.. 73. 2014
Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study.. 74. 2013
Racial disparities in knee and hip total joint arthroplasty: an 18-year analysis of national Medicare data.. 73. 2013
A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients.. 73. 2013
HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE.. 73. 2013
Tissue factor expression in neutrophil extracellular traps and neutrophil derived microparticles in antineutrophil cytoplasmic antibody associated vasculitis may promote thromboinflammation and the thrombophilic state associated with the disease.. 73. 2013
Validation of OMERACT preliminary rheumatoid arthritis flare domains in the NOR-DMARD study.. 73. 2013
Validation of the systemic lupus erythematosus responder index for use in juvenile-onset systemic lupus erythematosus.. 73. 2013
Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis.. 72. 2012
Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS).. 72. 2012
Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis.. 72. 2012
Association of joint space narrowing with impairment of physical function and work ability in patients with early rheumatoid arthritis: protection beyond disease control by adalimumab plus methotrexate.. 72. 2012
Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups.. 72. 2012
Functional genetic polymorphisms in ILT3 are associated with decreased surface expression on dendritic cells and increased serum cytokines in lupus patients.. 72. 2012
Incidence and predictors of secondary fibromyalgia in an early arthritis cohort.. 72. 2012
Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice.. 71. 2012
The role of varus and valgus alignment in the initial development of knee cartilage damage by MRI: the MOST study.. 72. 2012
A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry.. 71. 2012
Analysis of autosomal genes reveals gene-sex interactions and higher total genetic risk in men with systemic lupus erythematosus.. 71. 2011
IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus.. 71. 2011
IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction.. 71. 2011
Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial.. 71. 2011
Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort.. 71. 2011
Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire.. 70. 2011
Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.. 70. 2011
Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus.. 70. 2011
Vitamin D deficiency is associated with an increased autoimmune response in healthy individuals and in patients with systemic lupus erythematosus.. 70. 2011
Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial.. 70. 2011
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial).. 70. 2010
Varus and valgus alignment and incident and progressive knee osteoarthritis.. 69. 2010
Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine.. 69. 2010
Validation of a prediction rule for development of rheumatoid arthritis in patients with early undifferentiated arthritis.. 68. 2008
Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade.. 68. 2008
Is birthweight associated with risk of rheumatoid arthritis? Data from a large cohort study.. 68. 2008
The B lymphocyte stimulator receptor-ligand system in hepatitis C virus-induced B cell clonal disorders.. 68. 2008
A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies.. 67. 2008
Cigarette smoking, disease severity and autoantibody expression in African Americans with recent-onset rheumatoid arthritis.. 67. 2008
Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome.. 67. 2007
Histopathological prevalence of subchondral insufficiency fracture of the femoral head.. 67. 2007
Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.. 66. 2007
Assessment of the 2006 revised antiphospholipid syndrome classification criteria.. 66. 2007
Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients.. 65. 2006
Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis.. 65. 2006
Changes in plasma levels of fat-derived hormones adiponectin, leptin, resistin and visfatin in patients with rheumatoid arthritis.. 65. 2006
Real world experience with antiphospholipid antibody tests: how stable are results over time?. 64. 2005
Increased expression of humanin peptide in diffuse-type pigmented villonodular synovitis: implication of its mitochondrial abnormality.. 64. 2004
Immunohistochemistry of normal human knee synovium: a quantitative study.. 63. 2004
Patient Preference for Placebo, Acetaminophen (paracetamol) or Celecoxib Efficacy Studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis.. 63. 2004
Combined intravenous methotrexate and cyclophosphamide for refractory childhood lupus nephritis.. 63. 2004
Long term outcome of catastrophic antiphospholipid syndrome survivors.. 62. 2003
Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor alpha.. 62. 2003
Decreased flares of rheumatoid arthritis during the first year of etanercept treatment: further evidence of clinical effectiveness in the "real world".. 61. 2002
IgG subclass and light chain distribution of anticardiolipin and anti-DNA antibodies in systemic lupus erythematosus.. 47. 1988
Monocyte-induced inhibition of lymphocyte response to phytohaemagglutinin in progressive systemic sclerosis.. 42. 1983
Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City.. 80. 2021
Checkpoint inhibitor-induced polymyalgia rheumatica controlled by cobimetinib, a MEK 1/2 inhibitor.. 78. 2018
Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers.. 75. 2016
The risk of comorbidity.. 71. 2012
Rapid destruction of the hip joint in osteoarthritis.. 67. 2008
Anakinra treatment in patients with adult-onset Still's disease is fast, effective, safe and steroid sparing: experience from an uncontrolled trial.. 66. 2007
Subchondral insufficiency fracture of the femoral head in a patient with systemic lupus erythematosus.. 65. 2006
Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed?. 63. 2004
Response to: 'Correspondence on 'Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement'' by Manetti. 2020
Prevalence of clinically meaningful antiphospholipid antibodies in patients with systemic lupus erythematosus varies by race and ethnicity. 2023
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases. 2021
Genetic variants of STAT4 associated with rheumatoid arthritis in persons of Asian and European ancestry do not replicate in African Americans. 2010
Systemic sclerosis following human cytomegalovirus infection. 2002
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. 2012
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. 2011
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. 2010
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. 2008
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). 2003
Mitochondrial DNA haplogroups and ageing mechanisms in osteoarthritis.. 76. 2017
Provisional diagnostic criteria for polymyalgia rheumatica: moving beyond clinical intuition?. 71. 2012
Treatment of rheumatoid arthritis: strategies for achieving optimal outcomes.. 69. 2010
When does rheumatoid arthritis start and can it be stopped before it does?. 69. 2010
Disruptive innovation in rheumatology: new networks of global public-private partnerships are needed to take advantage of scientific progress. 2020
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019. 2019
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. 2019
A systematic literature review of strategies promoting early referral and reducing delays in the diagnosis and management of inflammatory arthritis. 2012
Diagnosis and management of adult onset Still's disease. 2005
Subchondral avascular necrosis: a common cause of arthritis. 1990
Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets. 2023
Anti-inflammatory therapy for COVID-19 infection: the case for colchicine. 2020
Variation in the ICAM1-ICAM4-ICAM5 locus is associated with systemic lupus erythematosus susceptibility in multiple ancestries. 2012
Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. 2010
Clinical implications of tumour necrosis factor alpha antagonism in patients with congestive heart failure. 1999

VIVO Weill Cornell Medical College

Annals of the rheumatic diseases Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)